通过可控制的向纳米材料进行多途径氧化应激放大,用于瘤的光免疫治疗
Song Li1, Yunheng Liu1, Xiaokang Zhang1
1School of Pharmacy, Binzhou Medical University, Yantai, 264003, China.
Journal of nanobiotechnology
|January 23, 2025
概括
这项研究介绍了一种有针对性的纳米系统,该纳米系统增强了用于协同瘤治疗的氧化应激. 这种新的方法结合了光热,光动力学和免疫疗法,以抑制瘤生长和逆转免疫抑制.
科学领域:
- 生物医学工程 生物医学工程
- 纳米技术纳米技术
- 癌症治疗 癌症治疗
背景情况:
- 光免疫疗法提供了改进的瘤治疗方法,但在活性氧物种 (ROS) 生产和药物分发方面面临挑战.
- 有针对性的药物输送系统对于提高治疗疗效和尽量减少副作用至关重要.
研究的目的:
- 开发一种可控制的,有针对性的纳米系统 (D/I@HST NP) 用于瘤的协同光热,光动力和免疫疗法.
- 通过多种途径增强氧化应激,以改善瘤治疗结果.
主要方法:
- 纳米粒子 (D/I@HST NPs) 用转素 (Tf) 表面修饰以准瘤细胞上的转素受体 (TfR).
- 利用808nm激光照射诱导ROS生产和药物释放.
- 利用酸性瘤微环境 (TME) 和铁还原酶来分裂二甲米西宁,产生额外的ROS.
- 集成的IR-780用于组合光动力学和光热效应.
主要成果:
- 该纳米系统展示了多途径氧化应激放大和协同治疗效应.
- 触发免疫细胞死亡,增强抗原释放和树突细胞成熟.
- 增加T细胞透和激活,导致瘤生长抑制和减少肺转移.
- 在瘤微环境中显著降低了髓质衍生抑制细胞.
结论:
- 开发的向纳米系统通过放大氧化应激和逆转免疫抑制TME,有效地抑制瘤.
- 这种方法为结合光疗和免疫疗法提供了一种有希望的策略,以加强癌症治疗.
- 为克服当前光免疫疗法方案的局限性提供了新的见解.
相关概念视频
Electron Transport Chain: Complex I and II
10.7K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
10.7K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K


